Zoetis (ZTS) Azione Prezzo
Zoetis Prezzo
Il fatturato è cresciuto a un tasso composto del 8,0% annuo negli ultimi 16 anni, raggiungendo 9,47 miliardi USD. L'utile per azione è cresciuto del 24,5% all'anno negli ultimi 15 anni. Il margine netto di Zoetis si attesta al 28,2%, in aumento rispetto al 26,2% di alcuni anni fa. Zoetis offre attualmente un rendimento da dividendo di circa il 2,55%. Il payout ratio è pari a circa il 33% degli utili. Il dividendo è cresciuto del 21,4% all'anno negli ultimi 12 anni. Gli analisti fissano un target di prezzo mediano di 85,00 USD, ovvero il 8,4% sopra il prezzo attuale. Su 24 analisti, 12 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Zoetis Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Zoetis Azione e analisi azionaria
Domande frequenti sull'azione Zoetis
Zoetis Inc. operates as a leading animal health company globally. The business model of Zoetis Inc. revolves around discovering, developing, manufacturing, and marketing a diverse range of animal health products and vaccines. With a focus on improving the health and well-being of animals, Zoetis aims to provide innovative solutions that enhance the health, productivity, and performance of livestock and companion animals. By offering a wide portfolio of products and services, Zoetis caters to the needs of veterinarians, livestock producers, and pet owners, thereby contributing to the overall welfare and sustainability of the animal health industry.
Zoetis Inc primarily operates in the animal health industry.
The main competitors of Zoetis Inc in the market are Merck & Co Inc, Elanco Animal Health Inc, and Boehringer Ingelheim GmbH.
Zoetis Inc is a leading global animal health company that specializes in the discovery, development, manufacture, and commercialization of a wide range of veterinary medicines and vaccines. Founded in 1952, Zoetis has a rich history of providing innovative solutions to improve the health and well-being of animals. With a strong commitment to research and development, the company has introduced numerous cutting-edge products and technologies that have revolutionized the field of animal health. Zoetis operates in more than 100 countries, serving veterinarians, livestock producers, and pet owners worldwide. This dedication to delivering high-quality, safe, and effective animal healthcare solutions has established Zoetis as a trusted name in the industry.
Zoetis Inc., a leading animal health company, has achieved several significant milestones in its history. Since its establishment in 2013 as a spin-off from Pfizer, Zoetis has continuously strived for innovation and growth. Some noteworthy milestones include its successful initial public offering (IPO) in 2013, becoming the largest animal health IPO in history. The company has also established itself as a global leader in animal health, expanding its presence in various markets worldwide. Additionally, Zoetis has consistently focused on research and development, introducing innovative products and solutions to address the health and well-being of animals. Through its dedication and expertise, Zoetis Inc. continues to make remarkable progress in the animal health industry.
Zoetis Inc., a leading animal health company, operates in various countries and regions worldwide. With a strong global presence, Zoetis primarily serves customers in North America, Europe, Africa, Asia, and Latin America. The company's extensive network allows it to deliver innovative animal health solutions and support to a diverse range of customers across these regions. Zoetis' commitment to expanding its reach and impact in the animal health industry is reflected in its presence and operations throughout these key locations.
Zoetis Inc represents a strong set of values and corporate philosophy. As a global animal health company, Zoetis Inc is committed to improving the health and well-being of animals by providing innovative products and services. With a focus on sustainability, they strive to make a positive impact on the world we live in. Zoetis Inc values integrity, accountability, collaboration, and customer focus. Their dedication to research and development ensures the delivery of high-quality solutions for animal health. By constantly evolving and embracing technological advancements, Zoetis Inc remains at the forefront of the industry, dedicated to improving the lives of animals, the people who care for them, and the communities they serve.
Gli analisti fissano attualmente un prezzo obiettivo medio di 99,17 USD per l’azione Zoetis (mediana: 85,00 USD), pari a +31,7 % rispetto all’ultimo prezzo. Il consenso si basa su 24 giudizi di analisti.
24 analisti valutano attualmente l’azione Zoetis: 12 raccomandano l’acquisto, 12 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Zoetis ricavi pari a 9,25 miliardi USD e un utile per azione di 6,28 USD.
Convertita al tasso di cambio attuale, l’azione Zoetis quota 69,92 EUR (78,42 USD).
L’azione Zoetis (ZTS) è quotata su 10 borse, tra cui: NYSE (ZTS), London (0M3Q.L), SIX (Zürich) (ZOE.SW), XETRA (ZOE.DE), Frankfurt (ZOE.F), München (ZOE.MU), Düsseldorf (ZOE.DU), Wien (ZOTS.VI).
Zoetis Inc is a leading company in the animal health industry that focuses on the development, manufacturing, and marketing of pharmaceuticals, vaccines, and diagnostic tests for animals. The company was founded in 1952 and is based in Parsippany, New Jersey. Zoetis operates in various segments including cattle production, swine production, poultry research and diagnostics, small animal practice, equine and livestock practice, and ectoparasiticides. The company offers several products that appeal to veterinarians and farmers. In the cattle range, Zoetis offers products such as EXCEDE, an injection that ensures sustained efficacy against pathogens in cattle, DRAXXIN, an injectable antibiotic for treating cattle with respiratory diseases and BRD, and LUTALYSE, a hormone that helps cattle breeders and livestock dealers during calving. In the swine production area, Zoetis offers products such as RESFLOR GOLD, a combination of antibiotics used for treating respiratory diseases, FOSTERA, a vaccine that provides immunity against Porcine Reproductive and Respiratory Syndrome (PRRS) and facilitates the approval of PRRS-infected swine, and DRAXXIN, a treatment for swine with respiratory disease. Zoetis is also involved in poultry research and diagnostics. Products such as FLOKILL, a medication for treating coccidiosis in chickens, Amprol, a medication for treating coccidiosis in chickens, Zeppelin, a test kit for identifying salmonella in poultry, and Bio-Chr, a feed additive that increases egg production in laying hens. In the small animal practice, Zoetis offers products such as Simparica, a medication for parasites like ticks and fleas in dogs, and Revolution and Proheart, both medications for parasites in dogs and cats. Zoetis also offers products for horses and livestock, including EQUIOXX, an anti-inflammatory for horses with arthritis and kissing spine, and CONVENIA, an antibiotic for horses, cows, and sheep. Zoetis is not only involved in the development and marketing of animal pharmaceuticals, but also in educating animal owners and farmers. They provide resources and training for animal health and care, and provide research data and information to animal owners. Zoetis' business model is to provide animal owners and farmers with innovative products and services that improve animal health and help keep animals healthy. The company specializes in developing and offering safe and effective products for animals used in food production to secure the food supply. Overall, Zoetis has a strong position in the animal pharmaceutical and diagnostic sector. The company aims to make a positive contribution to animals and animal owners through innovative products and close collaboration with animal owners.
Il attesa fatturato di Zoetis ammonta a 9,25 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Zoetis ammonta a 2,76 miliardi USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Zoetis è attualmente 12,48. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Zoetis.
Il rapporto prezzo/fatturato (P/S) di Zoetis è attualmente 3,72. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Zoetis.
Il Quality Score AlleAktien per Zoetis è 8/10.
L'ISIN di Zoetis è US98978V1035. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Zoetis è A1KBYX. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Zoetis è ZTS. Con questo simbolo di borsa vengono negoziate le azioni Zoetis in borsa.
Azione Zoetis
Gruppo di pari di Zoetis
Zoetis Ticker
Zoetis FIGI
Altre metriche e analisi di Zoetis in Deep Dive.
La nostra analisi azionaria dell'azione Zoetis include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Zoetis. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: